Access to the PPM Journal and newsletters is FREE for clinicians.

GeoPain App Allows Patients to “Paint” Pain on 3D Models for Efficiency

November 13, 2018
With precision, patients are able to better communicate their pain, leading to better therapy development and evaluation.

A PPM Brief

MoxyTech (Ann Arbor, MI), a University of Michigan startup, has launched1 GeoPain, an app that allows patients to “paint” their pain on multiple locations of a 3D human body to better map and track symptoms. Instead of using traditional pain scales, the app’s creators purport that visually mapping pain may give clinicians a better idea of the pain’s location, severity, its possible cause, and the best way to treat it.

Patients are able to help doctors identify the location and intensity of their discomfort, providing a more objective measurement of pain. Patients can input factors such as symptoms, triggers, and treatments over time; users can also show doctors a visual map of a pain flare long after the flare has ended. This allows for the analysis and communication of details that might be lost or misinterpreted with existing pain assessment methods. GeoPain users can also record pain details between appointments to build a comprehensive record to share with a doctor, which can integrate with a hospital or pain clinic’s cloud systems and devices.2

“Instead of trying to recall pain during a visit with their physician, patients can record the intensity and location of their pain as it occurs,” said Lynn Johnson, PhD, professor at the University of Michigan Dental School, in a press release.2 “This has never been possible before.”

The GeoPain app allows patients to be clear and precise when describing their pain. (Source: 123RF)

The app, initially created to track pain in patients enrolled in studies on migraine and chronic pain at the University, has shown that its data directly correlates with opioid activity in the brains of chronic pain patients, suggesting that it might be useful in clinical trials to measure the effectiveness of pain medication. Increased precision and decreased variability of the reporting of pain has potential benefits for pharmaceutical manufacturers, as these clinical trials could result in a better understanding of the efficacy of a drug while reducing both the number of patients and time to reach a conclusion.2

“We can dissect the pain with greater precision, in one patient or several, and across multiple body locations,” said Alexandre DaSilva, co-founder of MoxyTech and director of the Headache & Orofacial Pain Effort Laboratory at the University of Michigan School of Dentistry. “Whether the patient has a migraine, fibromyalgia or dental pain, we can measure whether a particular medication or clinical procedure is effective for each localized or spread pain condition.”

The free app is available via smartphone or tablet at Google Play and Apple’s App Store. MoxyTech plans to market the app’s data analytics to clinicians, healthcare systems, and pharmaceutical companies for use in developing better treatments for pain. GeoPain has already been tested at several clinics in Michigan with positive feedback.2

See GeoPain’s website to learn more.

Last updated on: January 15, 2019
Continue Reading:
Renewing Opioid Prescriptions Over the Phone
close X